Retifanlimab
- Generic Name
- Retifanlimab
- Brand Names
- Zynyz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2079108-44-2
- Unique Ingredient Identifier
- 2Y3T5IF01Z
- Background
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells...
- Indication
Retifanlimab is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
- Associated Conditions
- Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma
- Associated Therapies
- -
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT03532295
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States
πΊπΈWake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Combination Study of SV-BR-1-GM With Retifanlimab
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- BriaCell Therapeutics Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT03328026
- Locations
- πΊπΈ
Nebraska Cancer Specialists, Omaha, Nebraska, United States
πΊπΈSt. Joseph Heritage Healthcare, Santa Rosa, California, United States
πΊπΈSt Vincent-Frontier Cancer Center, Billings, Montana, United States
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 325
- Registration Number
- NCT03059823
- Locations
- π΅π±
Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland
π΅π±Medical University of Warsaw - 2Nd Department Obstetric and Gynecology, Warsaw, Poland
π΅π±Centrum Onkologii - Instytut Im. Marii Sklodowskiej - Curie, Warsaw, Poland
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 201
- Registration Number
- NCT02393248
- Locations
- πΊπΈ
Ohio State University - Wexner Medical Center, Columbus, Ohio, United States
πΊπΈSouth Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
πΊπΈUniversity of Michigan Health System, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.